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The use of radiation therapy to treat cancer inevitably involves exposure of normal tissues. Although the beneﬁts of this treatment
arewellestablished,manypatientsexperiencedistressingcomplicationsduetoinjurytonormaltissue.Thesesideeﬀectsarerelated
to inﬂammatory processes, and they decrease therapeutic beneﬁt by increasing the overall treatment time. Emerging evidence
indicates that PPARs and their ligands are important in the modulation of immune and inﬂammatory reactions. This paper
discusses the eﬀects of abdominal irradiation on PPARs, their role and functions in irradiation toxicity, and the possibility of using
their ligands for radioprotection.
1.Introduction
Recent advances in radiotherapy delivery, such as the devel-
opment of dose-sculpting techniques, have led to an overall
reduction in normal tissue exposure during radiation ther-
apy.Nevertheless, radiation toxicity tonormaltissueremains
the most important dose-limiting factor in radiotherapy
and is a major obstacle to uncomplicated cancer cure.
Gastrointestinal symptoms after pelvic radiotherapy aﬀect
the patient’s quality of life, are substantially more common
than generally recognized, and are frequently inadequately
managed [1, 2]. They develop because radiation induces
changes in one or more speciﬁc physiological functions in
widely separated parts of the gastrointestinal tract that lie in
the path of the radiotherapy beam.
Among the potential molecular targets for the treatment
or even prevention of these disturbances are peroxisome
proliferator-activated receptors (PPARs), a subclass of the
nuclear hormone receptor superfamily. The two PPAR
isotypes covered in this article have been identiﬁed in
vertebrates: PPAR-α, and PPAR-γ. The PPAR-α isoform is
abundantly expressed in the liver and is expressed as well
in the kidney, testes, heart, small intestines, pancreas and
smooth muscle. It is also detectable in the lungs, placenta,
and adipose tissue. PPAR-γ is speciﬁcally expressed at high
levels in the adipose tissue but is also detected in the
intestines, particularly the colon [3]. Relatively low PPAR
mRNA levels are observed in the skeletal muscle, liver, and
bone marrow stromal cells. In view of its expression and
involvement in immune response and cell proliferation,
PPAR-γ hasbecomeanespeciallyimportantresearchtopicin
gastroenterology, particularly in two important disorders—
inﬂammatoryboweldiseases(IBDs)andcoloncancer.Atthis
time, relatively little is known about the potential protective
and healing characteristics of PPAR-γ in radiotherapy-
induced bowel damage.
2.MolecularMechanismsofPPARActivity
2.1. Mechanism of Transcriptional Transactivation. The vari-
ety of their functions makes it diﬃcult to deﬁne the
molecular mechanisms of PPAR activity. PPAR-γ acts by
blocking gene transcription by transrepression, a feature of
transcriptional crosstalk between nuclear receptors (NRs)
and signaling cascades that modulates inﬂammation and
immunity in a variety of cells, including the epithelial cells
of the gut. Several models have been suggested to describe
transrepression by PPAR-γ interacting with the transcription
factor nuclear factor κB( N F - κB). NF-κBp l a y sa ni m p o r -
tant role in the regulation of immune and inﬂammatory
responses,foritinducestheexpressionofdiversetargetgenes
that promote cell proliferation, regulate apoptosis, facilitate2 PPAR Research
angiogenesis and, in carcinogenesis, stimulate invasion and
metastasis [4].
Inonecoactivatorcompetitionmodel,NF-κBandPPARs
use an overlapping set of coactivator proteins [5]a n d
compete with each other to bind to these coactivators. For
example, under steady-state conditions, some genes (e.g.,
iNOS) are occupied and actively repressed by the nuclear
receptor corepressor (NCoR) that serves simultaneously
to repress PPAR-mediated transcription. The switch from
repression to activation requires a reduction in aﬃnity for
the corepressor. In addition to the conformational change
in the ligand binding domain, ligand binding removes
NCoR complexes from promoters of nuclear receptor target
genes and thus increases aﬃnity for coactivators [6]. The
subsequent ﬁnding that transrepression still occurs in the
presence of excess coactivators [7] raises serious questions
about this model, however.
A second proposed model involves direct interactions
between nuclear receptors and negatively regulated tran-
scription factors, interactions that result in the inhibition
of the DNA-binding or transactivating activity of one or
both factors [5, 8]. In endothelial cell lines, for exam-
ple, PPAR-α activation inhibits the inﬂammatory response
by direct protein-protein interaction with NF-κBp65 [9].
Similarly, PPAR-γ inhibits the production of cytokines in
LPS-stimulated macrophages by direct interaction with NF-
κBp65/p50 [10]. In smooth muscle cells and hepatocytes,
PPAR ligands induce the expression of IκBα, which leads
to retention of the NF-κB subunits in the cytoplasm and
the consequent suppression of their DNA binding activity
[11]. It is worth pointing out that PPAR-γ ligands, besides
promoting PPAR-γ interaction with NF-κB subunits, may
also act independently of PPAR-γ. For example, the PPAR-
γ ligand 15d-PGJ2 inhibits the secretion of TNF-α and IL-
6 in macrophages stimulated by LPS and directly blocks
activity of the IκB kinase complex, completely independently
of PPAR-γ [12].
More recent studies have produced another model
involving a corepressor-dependent mechanism. Ligand-
binding of PPAR-γ induces the SUMOylation of a fraction
of some PPAR-γ molecules, which bind to NCoR and
prevent its clearance from the promoter. This leads to a
sustained repressed state. Using yeast two-hybrid screen
assays, Pascual et al. [13] showed that PPAR-γ interacts
with the protein inhibitor of the activated transcription
factor, STAT-1 (PIAS1). The physiological role of PIAS1 is to
facilitate the localization of PPAR-γ to the NCoR complexes
on the promoter of inﬂammatory genes, including iNOS,
in the presence of PPAR-γ ligands. Consequently, NF-κB-
mediated inﬂammatory gene expression is downregulated
[14].
2.2. Natural and Synthetic Ligands. PPAR-γ receptors are
activated by several natural lipophilic ligands, including
long-chain polyunsaturated fatty acids, arachidonic acid
metabolites derived from the cyclooxygenase, and lipoxy-
genase pathways (such as 15-deoxy-d-12,14-prostaglandin
J2 (15PG-J2) and 15-HETE) and fatty acid-derived com-
ponents of oxidized low density lipoproteins (OxLDLs)
(such as 9-hydroxyoctadecadienoic acid (9-HODE) and 13-
hydroxyoctadecadienoic acid (13-HODE) [15]. The antidi-
abetic class of thiazolidinedione drugs includes troglita-
zone, rosiglitazone, pioglitazone and ciglitazone, all syn-
thetic ligands of PPAR-γ. Other synthetic compounds
that can function as ligands include certain nonsteroidal
anti-inﬂammatory drugs (NSAIDs), such as indomethacin,
ibuprofen, ﬂufenamic acid, and fenoprofen [16]. Saturated
and unsaturated fatty acids are the primary natural PPAR-
α ligands, and eicosanoids and leukotriene β4 are among the
higheraﬃnityendogenousPPAR-αligands.Thebest-studied
synthetic PPAR-α ligands are the ﬁbrate class of hypolipi-
demic drugs (bezaﬁbrate, cloﬁbrate, and fenoﬁbrate), which
have been used therapeutically in humans for many years
[16].
3. Pathophysiology of Normal Intestinal
Tissue after PelvicIrradiation
Any clinician involved in the treatment of pelvic malig-
nancies with radiation is aware of the danger of colorectal
injury. Although the severe eﬀects were described long ago,
consideration of lesser degrees of colorectal injury is much
more recent [1, 2]. It remains diﬃcult to deﬁne exactly
when symptoms start to aﬀect quality of life and why
some people seek help for speciﬁc gastrointestinal symptoms
while others do not. The pathological processes of radiation
injury begin immediately after radiation exposure, but its
clinical and histological features may not become apparent
for weeks, months, or even years afterwards. Radiation
injury is commonly classiﬁed as acute, consequential, or late
eﬀects, according to the time of appearance of symptoms.
Acute (early) eﬀects are observed during the second week
of treatment (when histological changes probably reach
their zenith) and peak by the fourth to ﬁfth weeks (when
the histological changes have stabilized or are improving).
Some randomized studies show that the prevalence of mild
acute intestinal eﬀects ranges from 6 to 37% and severe
eﬀects (resulting in treatment interruption) from 0 to 10%
[17]. Consequential eﬀects appear later and are caused by
persistent acute damage [18]. They tend to peak at 18
months [19]. These symptoms concern fewer patients (half
ofthosewithlateeﬀects)butareclinicallyimportantbecause
of their chronic progressive nature and their signiﬁcant
long-term morbidity. Late eﬀects emerge months to years
after radiation exposure. Prevalence estimates of moderate
and severe late bowel eﬀects vary from 5% to 30% [20,
21]a n da ﬀect patients’ quality of life. Indeed 2.5% of all
pelvic radiotherapy patients require surgery as a result of its
complications.
Amongthemostcommonsideeﬀectsofpelvicradiother-
apy are acute radiation-induced proctosigmoiditis, enteritis
or colitis, depending on the symptoms and localization.
They result from delivering radiation to the distal colon
and rectum during radiotherapy that touches other pelvic
structures. The acute symptoms are pain and diarrhea or
constipation due to the loss of epithelial integrity and
increased mucus secretion. While the speciﬁc causes ofPPAR Research 3
constipation have not been investigated, the many causes of
diarrhea include accelerated small and large bowel transit,
bacterial overgrowth, and malabsorption of bile salts. Con-
sequently, the tissue develops edema, and hyperemia.
The most common late eﬀects include increased stool
frequency and urgency, spotting of blood, and partial
incontinence. Less common are ulceration, severe bleed-
ing, pain, stricture, severe incontinence, and ﬁstula [17].
Ulceration results from the tissue necrosis induced by the
release of radical species, persistence of the inﬂammatory
process, and the local ischemia associated with the vascular
damage. Severe complications, such as bleeding, ﬁstulas,
and obstruction, may require surgical intervention. Ischemia
and ﬁbrosis in the submucosa and muscularis layer are
mainly responsible for these eﬀects, which are accompanied
by vascular sclerosis, collagen deposition, and abnormal
ﬁbroblast activity. Compromised vascularization of ﬁbrotic
tissues[22] contributes to an adverse postoperative outcome,
and symptoms of this radiation enteropathy frequently
persist after surgery. Proctitis alone is estimated to account
for more than 75% of all gastrointestinal radiation injuries
[23] and usually begins in the second or third week of
radiotherapy. Acute radiation-induced proctosigmoiditis is
quite similar to distal ulcerative colitis, both in its symptoms
and its acute histopathologic eﬀects. Studies of patients
receiving bladder and prostate radiotherapy demonstrate
continued active inﬂammation and repair processes at 3
months after treatment [24]. The acute and chronic eﬀects
of radiation to the rectum appear to be correlated [25–27].
4. PPARS and Control of
GastrointestinalInﬂammation
4.1. Inﬂammatory Response. Inﬂammation is a major com-
ponent of early healing, and its control is essential for
eﬃcient repair. It plays a causative role in radiation-
induced toxicity. The ﬁrst observation of this inﬂammatory
process showed that levels of eicosanoids, leukotriene B4,
thromboxane B2, and prostaglandin E2 all rise markedly in
the rectum in response to pelvic irradiation and fall after
radiotherapy is complete [28]. Irradiation activates various
cell signaling pathways that lead to expression and activation
of proinﬂammatory and proﬁbrotic cytokines [29–32], to
vascular injury [33] and to activation of the coagulation
cascade [34, 35].
Intestinal homeostasis is generally maintained through
balanced immune and inﬂammatory responses, epithelial
integrity, and adequate lymphoepithelial interactions. Su et
al. [36] did essential work on the role of PPAR-γ in intestinal
inﬂammation, developing the ﬁrst model of colitis induced
by oral administration of dextran sodium sulphate [36, 37]
and showing the response of inﬂammation to treatment
by PPAR-γ ligands. Another model of colitis, induced by
intrarectal administration of 2,4,6-trinitrobenzene sulfonic
acid (TNBS), showed that treatment with troglitazone atten-
uates colitis [38]. Because it has been reproduced by acti-
vation of RXR with speciﬁc rexinoids, this beneﬁcial eﬀect
has been directly attributed to the RXR/PPAR-γ heterodimer
[38]. Further evidence in support of the involvement of
this heterodimer comes from the enhanced susceptibility
of PPAR-γ+/− and RXR+/− mice to TNBS-induced colon
inﬂammation [38]. The high expression of PPAR-γ in
epithelial cells suggests that these cells are the main target of
the RXR/PPAR-γ activators, and this hypothesis is reinforced
by the persistence of inﬂammation in deeper colonic layers
in animals treated with PPAR-γ or RXR agonists [38].
The use of exogenously administered PPAR-γ ligands
alone in this study left several questions open, especially
since only disease-activity measurements were considered,
rather than other objective colitis indicators. Can the anti-
inﬂammatory action of PPAR-γ activation be proved by
otherobjectiveindicatorsofcolitis-associatedinﬂammation?
Does endogenous PPAR-γ play an anti-inﬂammatory role in
physiological conditions? Are the levels of PPAR-γ protein
lower in IBDpatients than those in healthycontrolsand does
that make these patients more susceptible to chronic inﬂam-
mation? Nakajima et al. answered these questions, showing
not only that PPAR-γ ligands inhibit inﬂammation, but also
that a PPAR-γ deﬁciency is associated with aggravated injury
[39]. This report showed clearly that PPAR-γ functions as
anendogenousanti-inﬂammatorysubstanceintheintestines
and thus that a decrease in PPAR-γ levels may exacerbate
inﬂammation. IBD patients may have low levels of PPAR-γ
in their intestinal mucosa, potentially predisposing them to
unrestrained inﬂammation, as observed in PPAR-γ-deﬁcient
mice. Human studies are rare but appear to indicate that
patients with ulcerative colitis, but not those with Crohn’s
disease, have reduced levels of PPAR-γ p r o t e i ni nt h e i r
colonic epithelial lining [40]. This discrepancy between the
two diseases has not yet been explained.
Study of the role of PPARs in irradiation-induced
inﬂammatory process began only recently. Experiments in
our laboratory have measured the level of colonic PPARs
after abdominal irradiation. As in patients with ulcerative
colitis, PPAR-α,- γ, and heterodimer RXRα expression (of
both genes and proteins) fell drastically three days after
a single 10-Gy abdominal irradiation, and acute intestinal
injury was observed [41]. Similarly Zhao et al. showed
that whole-body irradiation downregulated PPAR-α and -γ
protein levels in the mouse kidney [42]. The PPARs, notably
PPAR-α and RXR-α, have been shown to be highly radiosen-
sitive, with PPAR repression observed from the ﬁrst doses
during a fractionated colorectal irradiation (4Gy/fraction,
3 fractions/week and total dose 52Gy) that mimicked a
radiotherapy protocol in a rat model (unpublished results).
In vivo, irradiation produces an acute and a chronic
increase in ROS generation that leads to persistent chronic
oxidativestress[43].PPARexpressionissensitivetooxidative
stress and to inﬂammatory processes, as shown by the
decreased PPAR-α expression induced by LPS or proinﬂam-
matory cytokines such as tumor necrosis factor-α (TNF-α)
[44]. In the acute phase of irradiation, the downregulation
of PPARs may be a mechanism that contributes to the
development or exacerbation of inﬂammation. Because
PPAR-γ/RXRα is highly expressed in epithelial cells and
given that irradiation may erode the epithelial layer, it was
thought that PPAR downregulation might well be correlated4 PPAR Research
with direct irradiation of the epithelium. But at the doses
delivered and during the experimental period, no epithelial
erosionwasobserved[41].Currently,wehavenoexplanation
for the impairment of PPAR expression that is induced by
irradiation. The direct impact of this impairment on the
severity of radiation enteritis remains to be determined.
Zhao et al. showed that the reduction of PPAR levels
aggravates radiation nephropathy [42]. Their study shows
that radiation-induced apoptosis is inhibited in PPAR-α
knockout mice by the enhanced activation of NF-κB and the
increased expression of prosurvival factors. The activation of
apoptosis signaling pathways prevents the DNA damage that
increasestheriskofgenomicinstability,mutations,andlong-
term carcinogenesis. The absence of this response in PPAR
knockout mice might thus increase carcinogenesis in these
mice.
Many molecular mechanisms and cellular targets play a
role in controlling colonic inﬂammation by PPAR expression
and activation in epithelial and various types of immune
cells, especially macrophages. Activation of PPAR-γ in
the colon inhibits mucosal production of inﬂammatory
cytokines (TNF-α,I L - 1 β, and IL-6) by downregulating the
NF-κBandMAPkinasesignalingpathways[38].Studieswith
cell culture models have established that PPAR-γ agonists
such as thiazolidinedione can reduce NF-κB activation and
inﬂammatory gene expression in colonic epithelial cells [45],
macrophages [46–48], dendritic cells [49], and T cells [50,
51]. Although the eﬃcacy of thiazolidinedione depends on
numerous factors including the cell model, concentration,
duration, type of thiazolidinedione (rosiglitazone, piogli-
tazone) used, and inﬂammatory model, it is nonetheless
generally accepted that these drugs can reduce inﬂammatory
gene expression.
In our laboratory we tested the strength of the reduc-
tion of the inﬂammatory process induced by GW1929, a
nonthiazolidinedione that has been identiﬁed as a high-
aﬃnity ligand for human PPAR-γ a n di sr e p o r t e dt o
be more potent than troglitazone [52]. Surprisingly, the
treatmentexacerbatedtheirradiation-inducedinﬂammatory
process, causing drastic weight loss and more severe mucosal
inﬂammation (unpublished results). These ﬁndings suggest
that it is absolutely necessary to analyze inﬂammatory and
immune status before treatment. No treatment is universal
for every inﬂammatory disease of the colon. Questions
remain about the role of inﬂammatory (macrophages, T
cells) and epithelial cells in PPAR response in other models
of acute and chronic enteritis, such as radiotherapy-induced
inﬂammatory intestinal response. The diversity of colitis
models may be helpful in demonstrating the importance of
targeting the speciﬁc ligand-activated PPAR.
4.2. PPARs and Macrophages. It is well established that
each PPAR isoform is expressed in monocyte/macrophage
lineages and inﬂuences their phenotypes [46]. In mono-
cytes/macrophages, PPAR-γ activation inhibits the expres-
sion of inﬂammatory cytokines such as TNF-α,I L - 1 β,a n d
IL-6.Similarly,inmacrophages,treatmentbyPPAR-γ ligands
induces a resting phenotype and suppresses iNOS [48].
These observations indicate that PPAR-γ might be a target
for anti-inﬂammatory therapy. More recently, studies with
mutations that disrupt one of the PPAR genes conﬁrm the
in vivo anti-inﬂammatory eﬀects of PPARs. Thus, Chawla
et al. [53] reported that both 15d-PGJ2 and troglitazone
exertanti-inﬂammatoryeﬀectsinmacrophagesderivedfrom
mice homozygous for a null mutation in the PPAR-γ gene
and therefore appear to work by a PPAR-γ-independent
mechanism.IntheirstudyofPPAR-γ-deﬁcientmacrophages,
Crosby et al. [54] showed that PPAR-γ is not necessary
for the successful inhibition of inﬂammatory mediators, in
particular, iNOS, by synthetic agonists.
Recently, we showed that 5-aminosalicyclic acid (5-ASA)
reduces the overexpression of TNF-α, MCP1, and iNOS that
isinducedduringtheacutephaseofirradiation.Theseeﬀects
could be seen by the reduction of macrophage inﬁltration
in the mucosa [41]. It thus appears to us that the role of
PPAR-γ may be overestimated in these irradiation protocols,
since the ligands are used at concentration exceeding those
required to bind PPAR-γ [53]. 5-ASA acts on inﬂammatory
processes even at the time when irradiation substantially
impairs PPAR/RXRα expression. These observations show
that the anti-inﬂammatory eﬀects of PPAR-γ ligands in
inﬂammatory cells may be independent of their ability to
activate PPAR-γ and may involve instead mechanisms such
as interference with early signals of the transduction cascade
that block NF-κB transcription (see Section 4.4).
In the past several years, studies of macrophages have
focused on their role as key cells of innate immune
system and their fundamental activities in killing and
removing foreign organisms and cell debris. Response to
macrophage stimulation is usually seen as proinﬂammatory
and proimmunogenic. More recently, diﬀerent forms of
macrophage activation have been proposed with nonin-
ﬂammatory and even anti-inﬂammatory consequences. A
state of macrophage activation, in response to infectious
agents, particularly Mycobacteria, involves IFNγ and other
cytokines, in conjunction with stimulation by LPS or other
Toll-like receptor (TLR) ligands. These so-called classically
activated or M1 macrophages have upregulated iNOS and
COX2. These cells play an important role in protection
against intracellular pathogens and cancer cells.
More recently, research has focused on the activation of
macrophages that produce inﬂammatory mediators. General
suppression is achieved after stimulation with IL-10, but
exposure to IL-4 or related cytokines initiates a so-called
“alternatively activated” or M2 macrophage [55]. Its capacity
for an oxidative burst, that is, to produce inﬂammatory
mediators, such as iNOS, in response to LPS, is reduced.
These cells have distinct functional properties, and are
integrated in polarized Th2 responses, tissue remodeling,
and repair [55].
Although suﬃcient data are not yet available,
macrophage polarization is an interesting vantage point
for studying the eﬀects of irradiation and their long-term
consequences.InaDanishclinicalstudyduringradiotherapy
of the pelvic-abdominal area, immunohistochemical
staining of the CD68 antigen showed increased density of
macrophages at 2 weeks (during the radiotherapy), butPPAR Research 5
no further change at 6 weeks (the end of the protocol).
The stained macrophages were localized mainly beneath
the epithelium in close proximity and intermingled
with other inﬂammatory cells in the lamina propria
[56]. In our laboratory fractionated irradiation of an
animal colorectal model conﬁrmed and extended these
observations; macrophage immunostaining increased over
the period of the protocol, while 6 months after the protocol
intended, staining was diminished compared with the
control animals [57].
In vivo, irradiation modulates the functional abilities
of some cells, in particular, NO production by activated
macrophages in an arthritis model [58]. Activation of
macrophages to produce iNOS depends on the dose deliv-
ered; a dose-dependent modulation of the NO pathway was
observed with radiation doses used in anti-inﬂammatory
radiotherapy and with superstimulation by the high radi-
ation doses used for cancer treatment. PPAR-γ expression
is not necessary for some macrophage functions, including
activation and diﬀerentiation of this cell lineage. PPAR-α is
thought to be involved in NO pathways, including in the
inhibition of iNOS expression by murine macrophages [59].
Inversely, PPAR downregulation is associated with the over-
expression of macrophage-related inﬂammatory mediators,
including iNOS, TNF-α, and MCP1, and with macrophage
inﬁltration [41] during the acute phase of irradiation.
Interestingly, 6 months after the end of the radiotherapy
protocol in the rodent, the PPAR level returned to normal
but iNOS expression was cut in half. A potential explanation
of this ﬁnding is that the modiﬁcation of macrophage
polarizationisalong-termeﬀectinducedbyirradiation.One
studyshowsthatperitonealresidentmacrophagesinducedby
the typical M2 inducers, IL-4, strong inducers PPAR-γ (gene
and protein) and thus suggests that high PPAR-γ activity is
preferentially associated with M2 [60]. Overall, it is clear that
theregulationofPPARsbypro-oranti-inﬂammatorysignals
is an important factor that triggers macrophage polarization.
The functional activity of irradiation-induced macrophages
and their involvement in long-term eﬀects (ﬁbrosis, lack of
response to infection) must be considered in this light.
4.3. Immune Response to Irradiation: PPAR Involvement.
Cytokines are especially important for regulating im-
mune and inﬂammatory responses with pro- and anti-
inﬂammatory functions, and perform crucial functions in
controlling both the innate and adaptive immune response.
Not only do cytokines govern the development and home-
ostasisoflymphocytes,buttheyalsodirectthediﬀerentiation
of helper T cells and promote the generation of memory cells
[61]. Immune-mediated damage to intestinal mucosal sur-
facescanbetriggeredbybothpolarizedTh1andTh2eﬀector
CD4+ T cells, and it can be improved or prevented. Three
functional categories of terminally diﬀerentiated immune
cells such as T helper (Th) cells have been characterized
on the basis of their cytokine production and homing
capacity: Th1 (IFN-γ,T N F - α, IL-12), Th2 (IL-4, IL13),
and regulatory Th cells (Treg) that produce IL-10 able to
inactivate Th1 and Th2. Th1 cells are mainly involved in cell-
mediatedimmuneresponses;whereasTh2cellsparticipatein
humoral responses and promote growth and diﬀerentiation
of mast cells and eosinophils. Because the Th1 and Th2
subpopulations tend to function antagonistically towards
one another, the persistence of disease susceptibility and
resistance depends on the cytokine proﬁle secreted by each
type. One molecular mechanism for cell polarization may
be the regulation of cytokine genes by transcription factors,
although the expression of these genes, such as that for
IFN-γ, can also be regulated at posttranscriptional stages.
InductionofT-bettranscriptionfactorexpressioninprimary
T cells is strongly correlated with Th1 lineage diﬀerentiation
and IFN-γ expression. In Th2 lineage diﬀerentiation and
expression of Th2 cytokines (IL-4, IL-5, and IL-13), on the
other hand, the GATA3 transcription factor plays a role
analogous to that of T-bet in Type 1 lineage diﬀerentiation
and IFN-γ expression. GATA3 expression polarizes T cells
towards a Th2 lineage and represses IFN-γ expression. It has
been suggested that the balance between T-bet and GATA3
expression is crucial for Th1/Th2 T-cell diﬀerentiation [62].
Recent reports show that ionizing radiation induces the
preferential diﬀerentiation of Th cells into Th2 cells in the
spleen[63,64]andmorerecently,intheintestines[65]where
this Th2 dominance is characterized by repression of Th1-
speciﬁc sets (IFN-γ, T-Bet). Indeed, irradiation initiates and
maintains a Th2-like immune response over the long term
[57]. Th2 cells play a critical role in the pathogenesis of
radiation-inducedpneumonitis,whichprecedeslungﬁbrosis
[66]. PPAR-γ involvement has previously been described in
the regulation of innate immune response [48], and more
recently its role has been investigated in adaptive immunity
[67, 68]. Although PPAR-γ is expressed on dendritic, T and
B cells, little is known about their speciﬁc expression of
PPARs, notably in colitis. PPAR-γ ligands have a negative
eﬀect on the APC functions of dendritic cells [69]. Remark-
ably, adoptive transfer of antigen-presenting dendritic cells
pretreated with PPAR-γ resulted in CD4+ Tc e l la n e r g y[ 70],
characterized by impaired diﬀerentiation that led to the
absence of both Th1 and Th2 cytokine production.
PPAR-α and PPAR-γ are diﬀerentially expressed after
lymphocyte activation. PPAR-α expression was downreg-
ulated after T cell activation while PPAR-γ expression
increased under the same activating conditions. PPAR
ligands inhibit the proliferation of T lymphocytes as well
as of B cells [71] and repress the production of IFN-
γ,T N F - α, and IL-2 [67]. Saubermann et al. [72] showed
that the reduction in inﬂammation induced by dextran
sodium sulphate, which has been noted with PPAR-γ ligand
treatment, is associated with decreased IFN-γ and TNF-α
andincreasedIL-4andIL-10expression.Consistentwiththis
shift towards Th2 cytokine dominance, treatment by PPAR-
γ ligands (troglitazone, pioglitazone, and rosiglitazone)
increases the expression of the speciﬁc Th2 transcription
factor, GATA-3. On the other hand, Jones et al. showed that
CD4+ T cells lacking PPAR-α produce high levels of IFN-
γ. These results indicate that the protective eﬀects exhibited
by PPAR-γ ligands in intestinal inﬂammation may be due to
immune deviation away from Th1 and towards Th2 cytokine
production. Surprisingly, by using another PPAR-γ ligand,
5-aminosalicylate, we restored the PPAR/RXR-α level and6 PPAR Research
normalized the downregulation of the irradiation-induced
IFN-γ/STAT1 pathway [57]. These results are inconsistent
with reports that PPARs negatively regulate IFN-γ and
presents an essential question: how may PPAR ligands
modulate the overexpression of IFN-γ in a Th1 model of
colitis and upregulate IFN-γ in Th2 colitis?
The twofold immunological eﬀect of PPAR ligands has
been observed in two diﬀerent acute lung inﬂammatory
models—carrageenan-induced pleurisy [73] and bleomycin-
induced lung injury [74]. In both, PPAR-γ ligands reduced
inﬂammatory cell inﬁltration (by neutrophils and possibly
otherleukocytes).OthershavehypothesizedthatPPAR-γ lig-
ands act by a direct eﬀect on the migration of inﬂammatory
cells in response to endogenous chemoattractant [75]. Other
studies show that PPAR-γ ligands may modulate leukocyte-
endothelial interactions during inﬂammation through the
regulation of endothelial adhesion molecules [74]. Consid-
erable evidence suggests that PPAR activation may limit the
endothelialresponsesthatpromoteTcelladhesionandentry
into the vessel wall.
PPAR ligands may act during several diﬀerent stages
of acute irradiation eﬀects. Firstly, PPARs may inhibit Th2
traﬃcking into the intestinal mucosa by interfering with the
endothelial adhesion molecules. Secondly, in vivo irradiation
leads to acute and chronic increases in ROS generation and
thus to persistent oxidative stress [43]. The free radicals
produced by irradiation cause vital cell damage that results
in the apoptosis of cells in the ﬁrst division or within the ﬁrst
fewdivisions.Someinﬁltratingcells,especiallymacrophages,
serveasthemajor sourceof inﬂammatorymoleculesand can
increase cell damage. Because Th1 cells are highly sensitive
to apoptosis [76], modiﬁcation of their oxidative status by
PPARs may help to normalize the Th1/Th2 balance. Thirdly,
we can rule out any direct action by PPAR ligands on
transcription factors. Although no synthetic inhibitors of
GATA-3 currently exist, PPAR-γ agonists have been shown
to inhibit GATA-3 expression and Th2-driven inﬂammatory
responses in murine models [77]. The yin-yang cytokine
balance of the Th1 and Th2 cytokines is a common feature
of inﬂammatory response and is thought to reﬂect the
operation of a feedback control mechanism. The eﬀects of
PPARs on T lymphocytes are thus complex and require
further study, especially in the ﬁeld of radiopathology.
Possible explanations for these observed diﬀerences include
PPAR-independent eﬀects of speciﬁc ligands or diﬀerences
in the model system used.
4.4. Possible Mechanisms: Crosstalk with Signal Transduction
Pathways. The mechanisms that perpetuate responses after
irradiation remain a mystery. No evidence of the expression
of immune cytokines (e.g., IL-2, IL-4, and IL-12) has
been found in irradiated mouse brains [78], but immune
mechanisms may have more importance in other tissues,
such as the lung and the intestine [65, 79]. Mitotic death of
speciﬁc cell populations responding to cell loss may result in
lethal damage at diﬀerent times after irradiation and “waves”
of responses. Other possible mechanisms include dysregu-
lated intercellular signaling due to the loss of speciﬁc cell
populations, the disruption of negative regulatory cytokine
pathways [80], or the development of hypoxia [81].
It is thought that PPAR-α and PPAR-γ repress inﬂam-
mation by physical interaction and form inactive com-
plexes with the proinﬂammatory transcription factors NF-
κB and Activating Protein1 (AP1) [82]. These transcription
factors normally induce the transcription of proinﬂamma-
tory genes, such as cytokines (IL-6, TNF-α), iNOS [83]
and COX-2 [84], chemokines (IL-8, MCP-1), and cellular
adhesion molecules (VCAM1, ICAM1). It has also been
suggested that PPAR-γ can interact with two transcription
factors, signal transducer and activator of transcription
(STAT) and nuclear factor of activated T-cells (NFAT),
and thereby reduce the transcription of proinﬂammatory
genes [82]. Another way in which PPAR-α and PPAR-γ
control inﬂammation is more indirect, by inﬂuencing the
transcription of genes that inhibit NFκB signaling, such
as IκBα and IKK. For example, ligand-activated PPAR-α
can induce expression of IκBα [9]. By linking to NFκB
subunits, it prevents the translocation of NFκB to the
cell nucleus and the subsequent transcription of proin-
ﬂammatory genes. The induction of IκBα via PPAR-α is
therefore positively correlated with decreased inﬂammation
and thus helpful in preventing or countering low-level
chronic inﬂammation. In the acute irradiation intestinal
model, the PPAR ligand 5-ASA also acted by overexpressing
IκBα and thus reducing nuclear translocation and activation
[41].
Several reports indicate that activated PPAR-γ crosstalks
with cytokine-mediated signal transduction pathways in
the modulation of immune response. Several lines of
evidence indicate that STAT signaling may be involved
in the anti-inﬂammatory action of PPAR ligands [85].
Wang et al. explored the interactions between PPAR-γ
and STAT3 in detail [86]. Two distinct PPAR-γ ligands
suppress IL-6 activated STAT3 through various types of
crosstalk including direct or mediated by the corepressor
SMRT (silencing mediator of retinoid and thyroid hormone
receptor). The exact mechanism through which PPAR-γ
represses STAT3 is not yet fully elucidated. Most stud-
ies of multiple myeloma cells show that the inhibitory
eﬀects of the PPAR-γ ligand on STAT3 activity depend
directly on the expression and activation of PPAR-γ [86].
A direct physical protein-protein interaction occurs between
n u c l e a rr e c e p t o rP P A R - γ and activated transcription factor
STAT3. Moreover, the enhancement of this interaction by
15-d-PGJ2, but not troglitazone, suggests that these two
classes of PPAR-γ ligands inactivate STAT3 through diﬀerent
mechanisms.
Interestingly in the intestinal irradiation model with
PPAR-α and PPAE-γ repressed (gene and protein levels),
STAT3 repression was also observed, again of both gene
and protein levels [41]. By normalizing PPAR expression, 5-
ASA elevated STAT3 protein levels (nucleus and cytosol). In
addition the direct eﬀect of PPAR-γ on STAT3 repression,
an alternative mechanism for PPAR ligand-mediated STAT3
expression, has been suggested, in which the PPAR ligand
acts indirectly by stabilizing inﬂammatory transcription
factor suppressor molecules [87].PPAR Research 7
Overwhelming evidence shows that STAT3 is the
only obligate factor required for IL-10-mediated anti-
inﬂammatory signaling [88]. In the mouse, thiazolidine-
dione treatment of acute colitis is accompanied by a
marked increase in IL-10 expression [71], especially in
mature dendritic cells and in activated CD4+ T cells; this
increase depends on both dose and PPAR-γ [49] when the
presence of a functional PPAR response element (PPRE)
in the IL-10 promoter region has been demonstrated. As
in colitis, intestinal irradiation represses IL-10 [89]a n d
all strategies that interfere with irradiation-induced NF-κB
activation restore the IL-10 level, including 5-ASA treatment
(unpublished results).
The obligate role of STAT3 in IL-10 signaling raises the
issue of pathway redundancy and speciﬁcity, for many recep-
tors use STAT3. For example, IL-6 signaling also activates
the STAT3 pathway but is incapable of activating the anti-
inﬂammatory response. One explanation involves the eﬀects
of suppressor of cytokine signaling 3 (SOCS3) on the IL-6
receptor. SOCS3playsanessentialroleasanegative inhibitor
of IL-6 by interfering with STAT3 [90]. Overexpression of
SOCS3 is observed immediately (3 hours) after intestinal
irradiation [89] and the SOCS3 level remains high for a long
time after irradiation ends (6 months) [57]. In our labora-
tory, we showed that interference with the NF-κBp a t h w a y —
either direct, by a speciﬁc inhibitor (CAPE), or indirect,
by PPAR activation (5-ASA)—normalizes the SOCS3 level
and in a roundabout way re-establishes the STAT3 level
[41, 65]. STAT3 phosphorylation continues for a prolonged
period in the absence of SOCS3 [90]. PPAR ligands can
activate anti-inﬂammatory pathways both dependently and
independently of IL-10, under the control of the negative
regulatory inﬂuence of SOCS3. The multiplicity of crosstalk
between nuclear receptors and transcriptional factors is an
important factor that contributes to signal diversiﬁcation
and speciﬁcation.
5. RadiotoxicityPreventionand Treatment
The improvement in survival after the development of
new schedules and techniques for delivering radiotherapy
underlines the importance of addressing the problems faced
by long-term survivors. Priority must be given to assessing
simplemethodsofpreventingboweltoxicityintheﬁrstplace,
without compromising either tumor control or prevention
of a secondary cancer. An earlier review of prophylactic
treatments for radiation toxicity failed to ﬁnd that any
current regimen was eﬀective [91].
Inthelate1970s,studiesshowedthat5-aminosalicylateis
the active moiety of sulfasalazine in patients with ulcerative
colitis and Crohn’s disease. Since then, this agent, its eﬃcacy,
drug proﬁle, precise indications, and adverse events have
remained topics of unceasing discussion [92]. At the same
time, controversy arose about the prevention of radiation-
induced bowel toxicity. A small double-blinded, balanced
and randomised trial study showed that acetylsalicylate was
eﬀective against the side eﬀects of uterine radiotherapy;
it reduced the number of bowel motions and relieved
abdominal pain [93].
More recently, Jahraus et al. conducted a double-blinded,
randomized, placebo-controlled trial of balsalazide and
observed a marked reduction in the classic symptoms of
acute radiation-induced proctosigmoiditis [94]. Balsalazide
is one of a class of functional drugs whose active metabolite
is 5-ASA. It inhibits the synthesis and release of proinﬂam-
matory mediators (NO, leukotrienes) and the function of
natural killer cells, mast cells, neutrophils, mucosal lympho-
cytes and macrophages [95]. These results were somewhat
surprising,sinceseveralotherlargerandomizedstudiesshow
that 5-ASA either does not improve or worsens the symp-
toms of acute radiation enteritis. Early randomized trials
of olsalazine [96] and mesalamine [97] were disappointing,
with mesalamine showing no beneﬁt and olsalazine showing
an increased incidence of diarrhea. The negative result for
olsalazine was not surprising, because a similar increase in
diarrhea prevalence was seen in IBD patients [98]. A study of
balsalazidefoundthatitdidnotsigniﬁcantlyalleviateclinical
symptoms [99]. In contrast, the randomized, double-blind
controlled trial of sulfasalazine conducted by Kilic ¸e ta l .i n
patients with a variety of pelvic radiotherapy malignancies
reached the opposite conclusion. This larger, controlled
study with a detailed grading of acute radiation enteritis
reportedthatnoneofthepatientsinthesulfasalazine-treated
group experienced Grade 4 diarrhea compared with the
placebo group [100].
The use of 5-ASA in radiation-induced gastrointestinal
complications has long been the topic of debate. It would
be more eﬀective if given before the radiotherapy insult
initiated the cascade of oxidative enzymes rather than after
this cascade has already begun [96]. At this time, these
inconsistent early clinical observations warrant further
investigation into the immunobiology of PPARs and their
potential role as a therapeutic target in the protection
of patients undergoing radiotherapy. Overall, the beneﬁt
of 5-ASA appears to depend on its dose, formula, and
mode of administration. The new-generation 5-ASA (i.e.,
Balsalazide), which produces a high concentration of active
drug in the colon, seems oﬀ to a promising start in making
pelvic radiotherapy more tolerable.
6.PPARLigand-AssociatedToxicities
Wound healing after injury is a high priority for survival.
In this situation, epithelial cells change their intracellular
contacts, modify their matrix, proliferate, and migrate over
the wound. Interestingly, each of these healing behavior is
similarly involved in tumorigenesis and metastasis. Epithelia
are highly susceptible to injury and also heal injuries
eﬀectively. At the same time, 95% of all cancer deaths are
from epithelial tumors. Together these facts suggest that the
repair mechanisms activated in response to injury may, if not
controlled, promote cancer.
Although PPARs may be involved in tumor-associated
pathways, their regulation of wound-healing genes within
speciﬁc tumors remains largely unexplored [101]. PPARs,
especially PPAR-γ, are expressed or overexpressed in sev-
eral abdominal malignancies, including colorectal carci-
noma [102, 103], prostate carcinoma [104], and pancreatic8 PPAR Research
carcinoma [105]. Another study reports that 8% of primary
colorectal tumors harbor a loss of function mutation in one
allele of the PPAR-γ gene and emphasizes the potential role
of this receptor as a tumor suppressor in humans [106].
In vivo evidence to support an antitumorigenic role of
PPAR-γ is also conﬂicting. Some experiments show that
PPAR-γ can behave as a ligand-activated tumor suppressor.
The ligands that activate PPAR-γ can inhibit proliferation
and induce diﬀerentiation and apoptosis of a wide range
of neoplastic cell types in vitro and in murine xenograft
tumor models. PPARγ−/− mice are more susceptible than
wild-type mice to mammary, colon, ovarian, and skin
tumors after exposure to carcinogens. PPAR-γ also enhances
tumor formation in some genetic models of cancer. Signif-
icantly, troglitazone reduced the tumor incidence in wild-
type but not heterozygote mice [107]. Chen et al. showed
that the PPAR-γ ligand 15-Deoxy-Δ12,14-prostaglandin J2
(15dPGJ2), or ciglitazone, induces apoptosis in HT-29 by
inhibiting NF-κB activity, which upregulates various anti-
apoptotic genes, and by suppressing the expression of BCL-
2, which protects cells against apoptosis [108]. In contrast,
however, both troglitazone and rosiglitazone treatments
increased the frequency and size of colon tumors in APCmin
mice, a clinically relevant model for both human familial
adenomatous polyposis and sporadic colon cancer [109,
110]. These mice have a germ-line mutation of the APC
gene resulting in deregulated β-catenin signaling and a very
signiﬁcantly increased frequency of small and large intestinal
adenocarcinomas. Subsequently, however, generation of the
APCmin bigenic mouse with an intestinal-speciﬁc PPAR-γ
deﬁciency demonstrated unequivocally that PPAR-γ sup-
presses tumor formation and suggested that thiazolidine-
dione has signiﬁcant oﬀ-target eﬀects in mice, especially in
the APCmin mouse colon cancer model [111]. These oﬀ-
target eﬀects of thiazolidinedione generally appear to have
broadanticancerousproperties;therefore,theﬁndingsinthis
model appear quite unusual.
Clinicalstudieshavenotyetprovidedaconclusiveanswer
to the question of whether PPAR-γ activity favors or inhibits
cancer formation and progression, but their outcome has
been largely disappointing and the clinical beneﬁts were
rather limited. The best results were obtained in three
patients with liposarcoma, in which lineage-appropriate dif-
ferentiation was induced [112]. At present, not enough evi-
dence is available to establish with certainly whether PPAR-γ
has pro- or antitumorigenic activities, and the ﬁeld remains
confusing. Some of this confusion, however, results from
diﬀerences in experimental design. First, the diﬀerentiation
state of the cells and tumors may aﬀect the outcome. PPAR-γ
activity is inﬂuenced by numerous other factors (cofactors,
mutations in genes such as APC, and diﬀerentiation status).
A ﬁnal point is that the concentration of PPAR-γ agonist
usedisimportant.Inbreastcancercelllines,forinstance,low
concentrations of PPAR-γ agonists induce cell proliferation;
whereas higher concentrations of the same agonists correlate
with cell cycle arrest and apoptosis [113]. A further point
worthstressingisthattroglitazone,acompoundwithsigniﬁ-
cant antioxidant properties, is reported to be associated with
the largest number of antitumorigenic eﬀects.
In contrast to normal cells and tissue, irradiation induces
a progressive but signiﬁcant tendency to overexpress PPAR-
γ in HT-29 at one day after irradiation. Surprisingly, trogli-
tazone treatment signiﬁcantly reduced irradiation-induced
PPAR-γ expression (personal communication) and may thus
contribute to the lack of eﬃcacy of its anticancer properties.
At this time no information is available about any hypothet-
ical deregulation of β-catenin signaling directly due to irra-
diation. Nonetheless, indirectly, irradiation is a nitric oxide
(NO) producer, and NO induces β-catenin degradation and
downregulates its transcriptional activity in colon cancer
cells,thusrevealingaso-far-unidentiﬁedmechanismofbeta-
catenin regulation [114]. The actions of these receptors
may be attenuated in malignancies by genetic, cytogenetic,
and environmental molecular mechanisms, which may com-
promise ligand generation. This understanding may have
important implications for the necessary molecular diagno-
sis required to target PPARγ therapies most eﬀectively.
7. Conclusion
The development of gastrointestinal dysfunction after pelvic
radiotherapy depends on a complex pathological process.
These gastrointestinal symptoms aﬀect the quality of life,
are substantially more common than generally recognized
and are frequently inadequately managed. They develop
because radiation can induce changes in one or more speciﬁc
physiological functions in widely separated parts of the
gastrointestinal tract that lie in the path of the radiotherapy
beam. The increasing weight of evidence suggesting a rela-
t i o nb e t w e e na c u t ea n dl a t ee ﬀects may encourage clinicians
to look at methods for decreasing tissue toxicity and thus
improving the patient’s quality of life. But decisions about
the treatment options for reducing radiotherapy toxicity
must be weighed after a careful beneﬁt-risk analysis that
depends on the target organ. Short-term preconditioning
strategies with PPAR agonists can be protective in several
animal models. Thus PPARs may provide a new strategy for
intestinal injury prevention in radiation toxicity as in IBD.
The tissue level of PPARs appears to be very radiosensitive.
Accordingly some additional experiments may be needed to
establish the mode of action of PPAR agonists in radiation
protection and the stage at which PPARs can inﬂuence
normal tissue self-renewal. A patient’s ability to respond to
appropriate therapy has a great impact on the actual toxicity
of the treatment. However, as mentioned previously, it
remainsunclearwhetherPPARsactasoncogenesorastumor
suppressors.Furtherstudiesareneededtoconﬁrmthiseﬀect,
especially in the absence of any eﬀect on tumor control.
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